Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. IMNN
8. NAVN
9. DFTX
10. META

Go back to Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge
(NASDAQ: CADL) Delayed: 9.15 --0 (-0%)
Previous Close $9.15    52 Week High $ 
Open $9.15    52 Week Low $ 
Day High $9.15    P/E N/A 
Day Low $9.15    EPS $ 
Volume 12,602